Hikma Pharmaceuticals PLC
HKMPFOTCHealthcare● Active
$19.07
+$1.07(+5.94%)
Market Cap$4.1B
P/E Ratio—
52W High$27.96
52W Low$16.3425
Hikma Pharmaceuticals PLC (HKMPF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HKMPF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 26, 2026EPS Actual
$1.08
Est. $1.08 · +0.0%
Revenue
$1.66B
Est. $1.66B · +0.0%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 26, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
HKMPF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | — | — | — | — | — | — |
| — Q1 FY2026 | Feb 26, 2026 | $1.08 | $1.08 | +0.0% | $1.66B | $1.66B | +0.0% |
| ▼ Q3 FY2025 | Aug 7, 2025 | $1.22 | $1.07 | -12.3% | $1.66B | $1.66B | +0.1% |
| — Q1 FY2025 | Feb 26, 2025 | — | $0.60 | — | $1.56B | $1.53B | +2.0% |
| — Q3 FY2024 | Aug 8, 2024 | — | $1.01 | — | $1.57B | $1.50B | +4.5% |
| ▼ Q2 FY2024 | Apr 25, 2024 | $0.96 | $0.27 | -72.0% | $1.47B | $1.37B | +7.3% |
| ▼ Q2 FY2023 | Jun 30, 2023 | $0.95 | $0.61 | -36.1% | $1.47B | $1.33B | +10.3% |
| ▼ Q4 FY2022 | Dec 31, 2022 | $0.78 | $0.07 | -91.0% | $1.34B | $1.24B | +8.0% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 26, 2026
EPS Actual
$1.08
EPS Est.
$1.08
EPS Surpr.
+0.0%
Revenue
$1.66B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
$1.07
EPS Est.
$1.22
EPS Surpr.
-12.3%
Revenue
$1.66B
Q1 FY2025
Feb 26, 2025
EPS Actual
$0.60
EPS Est.
—
EPS Surpr.
—
Revenue
$1.56B
Q3 FY2024
Aug 8, 2024
EPS Actual
$1.01
EPS Est.
—
EPS Surpr.
—
Revenue
$1.57B
Q2 FY2024
Apr 25, 2024Miss
EPS Actual
$0.27
EPS Est.
$0.96
EPS Surpr.
-72.0%
Revenue
$1.47B
Q2 FY2023
Jun 30, 2023Miss
EPS Actual
$0.61
EPS Est.
$0.95
EPS Surpr.
-36.1%
Revenue
$1.47B
Q4 FY2022
Dec 31, 2022Miss
EPS Actual
$0.07
EPS Est.
$0.78
EPS Surpr.
-91.0%
Revenue
$1.34B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Feb 26, 2026 | +0.0% | $21.95 | $19.06 | -13.17% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -12.3% | $26.38 | $26.38 | +0.00% |
| — Q1 FY2025 | Feb 26, 2025 | — | $28.92 | $27.17 | -6.05% |
| — Q3 FY2024 | Aug 8, 2024 | — | $23.43 | $25.02 | +6.79% |
| ▼ Q2 FY2024 | Apr 25, 2024 | -72.0% | $22.33 | $22.33 | +0.00% |
| ▼ Q2 FY2023 | Jun 30, 2023 | -36.1% | $23.10 | $23.10 | +0.00% |
| ▼ Q4 FY2022 | Dec 31, 2022 | -91.0% | $18.87 | $18.87 | +0.00% |
| ▼ Q2 FY2022 | Jun 30, 2022 | -23.4% | $18.19 | $18.19 | +0.00% |
Q1 FY2026-13.17%
Report Date
Feb 26, 2026
EPS Beat/Miss
+0.0%
Price Before
$21.95
Price After
$19.06
Q3 FY2025+0.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
-12.3%
Price Before
$26.38
Price After
$26.38
Q1 FY2025-6.05%
Report Date
Feb 26, 2025
EPS Beat/Miss
—
Price Before
$28.92
Price After
$27.17
Q3 FY2024+6.79%
Report Date
Aug 8, 2024
EPS Beat/Miss
—
Price Before
$23.43
Price After
$25.02
Q2 FY2024+0.00%
Report Date
Apr 25, 2024
EPS Beat/Miss
-72.0%
Price Before
$22.33
Price After
$22.33
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
-36.1%
Price Before
$23.10
Price After
$23.10
Q4 FY2022+0.00%
Report Date
Dec 31, 2022
EPS Beat/Miss
-91.0%
Price Before
$18.87
Price After
$18.87
Q2 FY2022+0.00%
Report Date
Jun 30, 2022
EPS Beat/Miss
-23.4%
Price Before
$18.19
Price After
$18.19
Avg Beat Reaction-13.17%
Avg Miss Reaction+0.00%
Beat Rate1 / 8 quarters
Largest Move-13.17% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HKMPF ends December
Hikma Pharmaceuticals PLC (HKMPF) most recently reported earnings on February 26, 2026 for Q1 FY2026, posting EPS of $1.08 (in line with the analyst consensus of $1.08). The next HKMPF earnings date is expected around September 1, 2026.
Each quarter, investors track HKMPF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HKMPF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HKMPF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HKMPF earnings · 4 questionsHikma Pharmaceuticals PLC's next earnings report is expected around September 1, 2026. HKMPF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HKMPF historically reports after market close (AMC).
HKMPF earnings datewhen is HKMPF earningsHKMPF next earnings datewhen does HKMPF report earningsHKMPF earnings calendar
▸ Source: FMP · Hikma Pharmaceuticals PLC SEC filings · US GAAP · Hikma Pharmaceuticals PLC SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026